Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Monoclonal antibodies have become important treatments for cancer, inflammation and a wide range of other diseases, representing an increasing share of the most successful pharmaceutical markets. The technologies to discover these drugs have been developed by select centers of excellence in industry and academia, and are continually being fine tuned in the race to identify the best antibody-based drug candidates and accelerate their paths to patients. The objective of this volume is to provide a series of guides to those evaluating and preparing to enter particular areas within the field and t

Immunoenzyme technique. --- Antibody-drug conjugates. --- Immunology --- Drug development. --- Pharmaceutical biotechnology. --- Biopharmaceutical technology --- Drugs --- Biotechnology --- Pharmaceutical technology --- Development of drugs --- New drug development --- Pharmacology --- Pharmacy --- Conjugates, Antibody-drug --- Drug-antibody conjugates --- Drug immunoconjugates --- Drug-immunoglobulin conjugates --- Immunoconjugates, Drug --- Immunoglobulin-drug conjugates --- Bioconjugates --- Immunopharmacology --- Antibody enzyme techniques, Unlabeled --- Immunoperoxidase technique --- Peroxidase labeled antibody technique --- Enzymatic analysis --- Immunoassay --- Protein binding --- Technique. --- Development --- Dosage forms --- Technique

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The concept of delivering ‘magic bullets’ to treat diseases was first proposed by Paul Erlich in the early 1900’s.  The realization of this concept for the treatment of cancer occurred in the late 1990’s with the approval of monoclonal antibody therapies.  The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy.  ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics.  More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use.  This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.

Antibodies. --- Antibody-drug conjugates. --- Immunotoxins -- Therapeutic use. --- Antibody-drug conjugates --- Antibody-toxin conjugates --- Diseases --- Pharmaceutical Preparations --- Immunoconjugates --- Immunoglobulins --- Therapeutics --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Immunoproteins --- Chemicals and Drugs --- Blood Proteins --- Proteins --- Amino Acids, Peptides, and Proteins --- Immunotoxins --- Neoplasms --- Drug Therapy --- Antibodies --- Drug Combinations --- Medicine --- Health & Biological Sciences --- Oncology --- Antibody-toxin conjugates. --- Conjugates, Antibody-toxin --- Immunoglobulin-toxin conjugates --- Toxin-antibody conjugates --- Toxin-immunoglobulin conjugates --- Conjugates, Antibody-drug --- Drug-antibody conjugates --- Drug immunoconjugates --- Drug-immunoglobulin conjugates --- Immunoconjugates, Drug --- Immunoglobulin-drug conjugates --- Medicine. --- Cancer research. --- Biomedicine. --- Cancer Research. --- Biomedicine general. --- Immune globulins --- Immune serum globulin --- Blood proteins --- Globulins --- Plasma cells --- Antibody diversity --- Antigens --- Bacterial immunoglobulin-binding proteins --- Cancer research --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Bioconjugates --- Immunopharmacology --- Immunotoxicology --- Toxins --- Drugs --- Dosage forms --- Oncology. --- Monoclonal antibodies. --- Antibodies, Monoclonal --- Monoclonal immunoglobulins --- Molecular cloning --- Tumors --- Health Workforce --- Biomedicine, general.